Amgen: Neoplasm Metastasis trials

The registry lists 39 Neoplasm Metastasis studies with Amgen as lead sponsor. 1 are open to participants now and 29 have results posted.

Phase 1 4Phase 2 10Phase 3 20Phase 4 4No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid TumorsRecruitingNCT07403721Phase 1
• Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)CompletedNCT03299244Phase 3Results posted
• Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver MetastasesCompletedNCT03256344Phase 1Results posted
• A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving HaemodialysisCompletedNCT02833857Phase 1Results posted
• Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on DialysisCompletedNCT02341417Phase 3Results posted
• Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on DialysisTerminatedNCT02138838Phase 3Results posted
• Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on HemodialysisCompletedNCT02102204Phase 3Results posted
• Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to EtelcalcetideCompletedNCT01932970Phase 3Results posted
• Head-to-Head Study of Etelcalcetide (AMG 416) and CinacalcetCompletedNCT01896232Phase 3Results posted
• Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on HemodialysisCompletedNCT01788046Phase 3Results posted
• Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on HemodialysisCompletedNCT01785875Phase 3Results posted
• Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on HemodialysisCompletedNCT01785849Phase 3Results posted
• Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary HyperparathyroidismTerminatedNCT01439867Phase 2Results posted
• Open-Label Access Protocol of Denosumab for Subjects With Advanced CancerCompletedNCT01419717Phase 3Results posted
• Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple MyelomaCompletedNCT01345019Phase 3Results posted
• Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)CompletedNCT01327612Phase 2Results posted
• Study to Evaluate Cinacalcet in Children With Chronic Kidney DiseaseCompletedNCT01290029Phase 1Results posted
• Pediatric Chronic Kidney Disease Safety and EfficacyTerminatedNCT01277510Phase 3Results posted
• Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing HemodialysisCompletedNCT01181531Phase 4Results posted
• Open Label Extension to SRE Studies in United Kingdom and Czech Republic OnlyCompletedNCT00950911Phase 3Results posted
• 20070360 Incident DialysisCompletedNCT00803712Phase 4Results posted
• Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.CompletedNCT00330759Phase 3Results posted
• Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate CancerCompletedNCT00321620Phase 3Results posted
• A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.CompletedNCT00321464Phase 3Results posted
• Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate CancerCompletedNCT00286091Phase 3Results posted
• Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal DiseaseCompletedNCT00261950Phase 2Results posted
• Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) BisphosphonatesCompletedNCT00104650Phase 2Results posted
• Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast CancerCompletedNCT00091832Phase 2Results posted
• Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin ChemotherapyCompletedNCT00083616Phase 2Results posted
• Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency PatientsCompletedNCT00042432Phase 2Results posted
• Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the JawCompletedNCT01998607
• Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver MetastasesCompletedNCT00866944Phase 2
• ACHIEVE: Optimizing the Treatment of Secondary HyperparathyroidismCompletedNCT00135304Phase 4
• START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary HyperparathyroidismCompletedNCT00132431Phase 4
• SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary HyperparathyroidismCompletedNCT00117052Phase 3
• ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)CompletedNCT00101920Phase 2
• A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on DialysisCompletedNCT00042653Phase 3
• A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis PatientsCompletedNCT00037635Phase 3
• ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)CompletedNCT00034346Phase 2